Chelsea Therapeutics International, Ltd.
http://www.chelseatherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chelsea Therapeutics International, Ltd.
Finance Watch: More Job Cuts As Companies Prioritize Cash Conservation
Public Company Edition: Applied Molecular Transport, Scholar Rock, Agios and others join many of their peers in revising their strategies and downsizing their teams. Also, Zentalis grossed $200m from a follow-on offering and OKYO Pharma went public in the year’s smallest biopharma IPO in the US.
Quanta CEO Speaks On US Expansion, Talent Acquisition, And Addressable Markets
Since closing its $245m funding raise, Quanta Dialysis Technologies has been scaling up its commercial infrastructure and bolstering its US presence.
SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors
While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.
Japan Lifts Decades-Old Bans On Somatropin In Diabetes, IFNβ In Pregnancy
Japan cautiously lifts decades-old bans on somatropin’s use in diabetic patients and interferon beta 1a/1b in pregnant patients, judging benefits can outweigh risks and following requests from doctors and pharma firms to consider patients.